

1 ORIGINAL RESEARCH

2 Mike Du et al

3 Random effects modelling vs logistic regression for the inclusion of
4 cluster level covariates in propensity scores for medical device and
5 surgical epidemiology

6 **Author name:** Mike Du^{1†}, Albert Prats-Urbe^{1†}, Sara Khalid¹, Daniel Prieto-Alhambra¹, Victoria Y Strauss^{1^}, Sara
7 Khalid^{1^}

8 **Author affiliations**

9 ¹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre,
10 Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK

11 †These authors contributed equally to this work.

12 ^Joint senior authors

13 **Correspondence:** Daniel Prieto-Alhambra

14 Botnar Research Centre, Windmill Road, OX3 7LD, Oxford, UK.

15 E-mail: daniel.prietoalhambra@ndorms.ox.ac.uk

16 **Abstract**

17 **Purpose**

18 Surgeon and hospital related features such as surgeries volume can be associated with treatment
19 choices and treatment outcomes. Accounting for these covariates with propensity score (PS) analysis
20 can be challenging due to clustered nature of the data. Previous studies have not focused solely on
21 the PS estimation strategy when treatment effects are estimated using random effects model(REM).
22 We studied PS estimation for clustered data using REM compared with logistic regression.

23 **Methods**

24 Six different PS estimation strategies were tested using simulations with variable cluster-level
25 confounding intensity (odds ratio(OR)=1.01 to OR=2.5): i) logistic regression PS excluding cluster-
26 level confounders; ii) logistic regression PS including cluster-level confounders; iii) same as ii) but
27 including cross-level interactions; iv), v) and vi), similar to i), ii) and iii) respectively but using REM
28 instead of logistic regression PS. Same analysis were tested in a randomised controlled trial
29 emulation of partial vs total knee replacement surgery. Simulation metrics included bias and mean
30 square error (MSE). For trial emulation, we compared observational vs trial-based treatment effect
31 estimates.

32 **Results**

33 In most simulated scenarios, logistic regression including cluster-level confounders gave more
34 accurate estimates with the lowest bias and MSE. E.g. with 50 clusters x 200 individuals and
35 confounding intensity OR=1.5, the relative bias= 10% and MSE= 0.003 for (i), compared to 21% and,
36 0.010 for (iv). In the Trial emulation, all 6 PS strategies gave similar treatment effect estimates.

37 **Conclusions**

38 Logistic regression including patient and surgeon/hospital-level confounders appears to be the
39 preferred strategy for PS estimation. Further investigation with more complex clustered structure is
40 suggested.

41 **Keywords:**

42 propensity score, simulation, trial emulation, clustered data, random effects model, causal inference

43

44 **Competing interests:**

45 Prof. Prieto-Alhambra's research group has received grant support from Amgen, Chesi-Taylor,
46 Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from
47 Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker
48 services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF
49 consortiums, and Synapse Management Partners have supported training programs organised by
50 DPA's department and open for external participants organized by his department outside
51 submitted work.

52

53 **Ethics Approval and Informed Consent**

54 This study was approved by the secretary of state, having considered the recommendation from the
55 Confidentiality Advisory Group (CAG reference: 17/CAG/0174). Informed ethical approval was given
56 on the use of pseudonymised patients data included in the study.

57

58

59

60

61

62

63

64

65

66 **INTRODUCTION**

67 Observational studies using routinely collected patient data from health registries are often used for
68 clinical treatment comparative study when randomised control trials are unfeasible or unethical(1).
69 Conversely to randomisation in trials, treatment allocation in observational data is often driven by
70 patient and physician features, leading to confounding by indication. First proposed by Rosenbaum
71 and Rubin(2, 3), propensity score (PS) weighting are a popular method to minimise the resulting
72 bias. Most PS applications in pharmacoepidemiology include only patient covariates. Conversely,
73 medical device and surgical studies typically have a clustered structure that accommodates hospital
74 and physician/surgeon features that could impact treatment and outcome and hence act as
75 confounders(4, 5).

76 Several simulation studies have shown that using random effects models(6) in the PS estimation or
77 treatment outcome modelling can reduce the bias arising from cluster level confounding in clustered
78 data(7-12). However, it is unclear whether random effects models should be used for both PS
79 estimation and outcome modelling in observational studies of medical devices or surgical
80 procedures. Therefore, this study aims to evaluate to what extent random effects model should be
81 used for PS estimation when random effects model is used to estimate the treatment outcome. This
82 study aimed to assess to what extent random effects model should be used for clustered
83 observation studies of medical device and surgical epidemiology.

84 We used Monte Carlo simulations(13), and a surgical trial emulation study comparing partial and
85 total knee replacement surgery to evaluate the accuracy and precision of random effects model
86 compared to logistic regression propensity score model.

87

88

89

90 **METHODS**

91 **Simulation data generation process**

92 The simulation settings were based on previous simulation studies(7, 8) but with parameters
93 adapted to medical device/surgical epidemiology data. We simulated clustered datasets via Monte
94 Carlo simulations with a fixed sample size of 10,000 individuals to represent the patients, binary
95 treatment allocation (T) and binary outcome (Y). The complete mathematical formulae for data
96 generation are included in the supplementary material. We simulated six individuals-level covariates
97 (x1 to x6), two cluster-level covariates (z1 and z2 to represent the hospital/surgeon level covariates)
98 and a cross-level interaction term between the individual and cluster-level confounder for each
99 individual. Among the individual covariates simulated, 5 were confounders (x1- x5), 1 was a risk
100 factor associated with outcome but not with exposure (x7), and 1 was an instrumental variable (x6).
101 Both cluster level covariates (z1 and z2) were generated as confounders. Figure 1 gives the clustered
102 causal diagram of the simulation covariates.


103 12 different scenarios with 1000 replications under each scenario were simulated to test: 1) three
104 different ratios of cluster: individual size: 10: 1000, 50: 200, and 500: 20; 2) different effect size for
105 z1 and z2 on outcome, ranging from negligible with odds ratio = 1.01 (resembling an instrumental
106 variable) to strong with odds ratio = 2.5 (equivalent to strong multilevel confounding). Table 1 gives
107 the generation distribution, effects on treatment allocation and effects on treatment outcome for all
108 the covariates generated in the simulations.

109 The simulation data were generated with simstudy (version 0.2.1) R package, and the propensity
110 score models were fitted with lme4 (version 1.1.21) R package.

111

112

113 Figure 1: This diagram gives the causal relationship between the covariates in the simulation data, the arrow indicates
114 causes. For example, $x1 \rightarrow Y$ implies $x1$ causes Y .



115

116

117

118

119

120

121

122

123 *Table 1: The table gives the generation distribution, effects on treatment allocation and effects on treatment outcome for*
 124 *covariates generated in the simulations. OR = odd ratio*

Covariates	Description	Effects on treatment allocation (beta value)	Effects on treatment outcome (Beta value)	Generation distribution
z1,z2	Cluster-level confounders	$z1 = z2 = 0.4055$ (equivalent to OR=1.5)	$z1 = z2 =$ [0.01,0.2231,0.4055,0.9163] ~ [equivalent to OR =1.01,1.25,1.5,2.5]	$z1 \sim N(0,1),$ $z2 \sim \text{Bernoulli}(0.5)$
x1 to x5	Individual level confounders	$[x1,x2,x3,x4,x5] =$ [0.35,0.4,0.45,0.5,0.55]	$[x1,x2,x3,x4,x5] =$ [0.35,0.4,0.45,0.5,0.55]	$[x1,x2,x3] \sim \text{Bernoulli}$ ([0.4,0.45,0.5]) $x4,x5 \sim N(0,1)$
x6	Individual level risk factor	0	0.5	$\text{Bernoulli}(0.5)$
x7	Individual level instrumental variable	0.5	0	$\text{Bernoulli}(0.5)$
z1*x1	Cross level interaction term	0.4055 (OR =1.5)	0	$z1*x1$

125

126

127

128

129

130

131 **Propensity score estimation strategy**

132 For all the data scenario described in the simulation data generation process, we tested six different
133 strategies to incorporate propensity score, as defined in Table 2.

134 *Table 2: The table gives the cluster level information contained and the statistical models used for the six propensity score*
135 *estimation strategies (M1 to M6).*

Propensity score strategy	Cluster level confounders as covariates in PS model	Cross level confounders interaction term as covariate in PS model	Statistical model to build a propensity score
M1	Excluded	Excluded	Logistic regression
M2	Included	Excluded	Logistic regression
M3	Included	Included	Logistic regression
M4	Excluded	Excluded	Random effects model ¹
M5	Included	Excluded	Random effects model ¹
M6	Included	Included	Random effects model ¹

136 ¹ The random effects model were built with logit link function

137

138

139

140 **Treatment effect estimation**

141 For each of the scenarios, the average treatment effect (ATE) was estimated using random effects
142 models with logit function regress on treatment outcome weighted with stabilised inverse
143 probability weighting (SIPW)(14) based on propensity scores calculated using the strategies
144 described in table 2. Random effects model was use for treatment effect estimation since several
145 simulation studies on propensity score(7, 8) have shown that using random effects models to
146 account for the cluster level confounding generally gives the least bias.

147 **Assessment of simulation results**

148 We measured each propensity score specification strategy's performance on each scenario by
149 calculating the 1) absolute relative bias (%), defined as the average percentage difference between
150 the true treatment effect and the estimated treatment effect. 2) mean square error (MSE), which is
151 a measure of accuracy. 3) 95% confidence interval model coverage, defined as the proportion of the
152 95% confidence intervals of the estimated treatment effect effects containing the true treatment
153 effect. All the performance measures were calculated following the simulation study guidelines
154 discussed in Morris et al(15) with “rsimsum” (version 0.9.1) R package.

155 **Case study on medical device and surgical epidemiology**

156 We used data from the UTMOST study(16), which aimed to identify the optimal methods for
157 controlling confounding when emulating the results of the TOPKAT surgical trial(17). The UTMOST
158 cohort study included patients with a first primary total knee replacement (TKR) or
159 unicompartmental knee replacement (UKR)(18) in the UK National Joint Registry (NJR) from 2009 to
160 2016 who would have met the TOPKAT trial eligibility criteria. UTMOST included a total of 294556
161 patients (294556 UKR and 21,026 TKR patients), and 6420 different lead surgeons carried out the
162 interventions. UTMOST extracted 18 patient-level covariates from the NJR, linked to Hospital
163 Episode Statistics (HES) records and patient-reported outcome measures, and the volume of UKR

164 performed by each lead surgeon in the previous year from the NJR. The UTMOST study outcome was
165 revision five years after surgery. Table 3 gives the covariates adjusted in the study.

166 We applied the six proposed propensity score specification strategies from table 2 to the UTMOST
167 dataset to construct the propensity scores for UKR and compared it to the results of the TOPKAT
168 surgical trial. The cross-level interaction term considered in UTMOST was the interaction of surgeon
169 volume and patient gender. As with the simulated data described in the method section, we
170 modelled the 5-year revision risk for patients received UKR using a random effects model with the
171 lead surgeon as cluster level while covariates were adjusted with stabilised inverse probability
172 weights.

173

174

175

176

177

178

179

180

181

182

183

184

185 *Table 3:: This table gives the covariates adjusted in the case study. UKR = unicompartmental knee replacement NJR =*
 186 *National Joint Registry. 1 standardised measure of health-related quality of life developed by the EuroQol Group*

Covariates	Type/description
Socio-demographic covariates	Patient covariates (individual level)
Age	Continuous covariate
Gender	Binary covariate
Rural Urban	Categorical covariate – urban/town and fringe/village/isolated
IMD	categorical covariate in 10 percentiles from least deprived to most deprived
BMI	Continuous covariate
Pre-Operative Patient Reported Outcomes	Patient covariates (individual level)
pre-operative OKS	Continuous covariate
EQ-5D ¹	Continuous
General health	Categorical covariate with discrete scale excellent/1/2/3/4/poor
Comorbidities 3-year before surgery	Patient covariates (individual level)
Charlson comorbidity	Binary covariate
Gastrointestinal disease	Binary covariate
Osteoarthritis and other joint problems	Binary covariate
Mental health	Binary covariate
Respiratory disease	Binary covariate
Cardiovascular disease	Binary covariate
Thyroid problems	Binary covariate
Foot, hip, spinal pain	
Foot, hip, spinal pain	Binary covariate
Coxarthrosis	Binary covariate
Neurological disorders	Binary covariate
Other arthrosis	Binary covariate

Polyarthrosis	Binary covariate
Spondylosis	Binary covariate
Surgeon's feature covariates	Surgeon covariates (cluster level)
Surgery volume of UKR performed by each lead surgeon in the previous year from the NJR	Continuous covariate

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203 RESULTS

204 Simulation study

205 Figures 3 and 4 gave the simulations average absolute relative bias and MSE of the treatment effect
206 estimates for propensity score estimation strategy M1 to M6. There were few clear trends appeared
207 from figure 3 and 4 that were consistent in all cluster structure scenario. The relative bias and MSE
208 for models with and without the cross-level interaction were similar, for example, relative bias =
209 9.42% in M2 and relative bias = 9.53% in M3 for cluster level confounders odd ratio (OR) = 1.01,
210 cluster structure (10,1000) scenario, suggesting that not incorporating the cross-level correlation
211 where there is one did not impact on bias much. In scenarios where the cluster level confounders
212 had minimal effect on outcome (OR = 1.01), the model where propensity score without cluster level
213 confounders in the logistic regression (M1) gave the lowest bias when compared to other PS models.
214 By contrast, M1 did not always gave lowest relative bias and MSE when the effect size of cluster
215 level confounders OR were greater than 1.01.

216 For cluster structure with small cluster number and large cluster size ($m = 10, n = 1000$) and ($m = 50,$
217 $n = 200$) using random effects model for propensity score estimation (M4, M5, M6) consistently gave
218 higher bias compared to using logistic regression model (M1, M2, M3). For example, the relative bias
219 for M4 is 21.1% compared to 9.53% for M1 in cluster structure ($m = 50, n = 200$) and cluster level
220 confounders effect size odd ratio 1.5 scenario. Also, adding the cluster level confounders as
221 covariates in the propensity score model did not impact the bias much in cluster number (m), cluster
222 size (n) = [(10,1000), (50,200)] scenarios regardless of the cluster level confounder effect size on the
223 treatment outcome. Since the relative bias for M1 compared to M2 and M3, and the relative bias
224 M4 compared to M5 and M6 are very similar.

225 The results for the smallest cluster size scenarios ($m = 200, n = 50$) behaved differently compared to
226 the other two cluster structures tested in the study. Apart from in the cluster confounder effect on

227 outcome OR = 1.01 scenario. The relative bias for propensity score strategy that either included the
228 cluster level confounders as covariates in the propensity score model or used a random effects
229 model to account for the cluster structure of the data (M2 to M6) reduced bias compared to
230 propensity score strategy did not consider the cluster level (M1). The improvement in bias and MSE
231 was greater as the cluster level confounders effect on outcome increases. For example, the relative
232 bias for M1 = 14.02% compared to M2 = 9.48% for cluster level confounders effect on outcome OR =
233 1.5. For cluster level confounders effect size on outcome OR = 2.5, the relative bias for M1 = 20.16%
234 compared to M2 = 10.54%.

235

236

237

238

239

240

241

242

243


244

245

246

247

248 *Figure 2: The graphs give the simulation treatment effects average absolute relative bias and 95% confidence interval for*
 249 *propensity score specification strategies M1 to M6 for different cluster structure and cluster (surgeon) level confounder*
 250 *ratio on treatment outcome. Structure = (number of clusters, individuals per cluster), surgeon OR = cluster level confounder*
 251 *odd ratio on treatment outcome. Propensity score(PS) strategies: M1 = logistic regression PS excluding cluster-level*
 252 *confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with cluster level*
 253 *confounders and cross level interaction term, M4 = random effects PS excluding cluster-level confounders, M5 = random*
 254 *effects PS including cluster-level confounders, M6 = random effects PS with cluster level confounders and cross level*
 255 *interaction term*



256

257

258

259


260

261

262

263


264 Figure 3: The graphs give the simulation treatment effects average mean square error and 95% confidence interval for
 265 propensity score specification strategies M1 to M6 for different cluster structure and cluster (surgeon) level confounder
 266 ratio on treatment outcome. Structure = (number of clusters, individuals per cluster), surgeon OR = cluster level confounder
 267 odd ratio on treatment outcome. Propensity score(PS) strategies: M1 = logistic regression PS excluding cluster-level
 268 confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with cluster level
 269 confounders and cross level interaction term, M4 = random effects PS excluding cluster-level confounders, M5 = random
 270 effects PS including cluster-level confounders, M6 = random effects PS with cluster level confounders and cross level
 271 interaction term



272

273 Figure 4 gave the 95% CI model coverage for the simulation study. It showed that low coverage was
 274 a major issue for treatment effects estimates using random effect model based propensity score
 275 model (M4 to M6) when the cluster size was large (n = 1000 and n = 200) as the model coverage for
 276 M4 M5 M6 were much lower than M1 M2 M3. In our small cluster size scenario (n = 20), the model
 277 coverage between M4 M5 M6 and M1 M2 M3 were more closely matched. However M2 and M3 still
 278 gave higher model coverage then M4 M5 M6.

279 Figure 4: The graphs give the simulation treatment effects average 95%CI model coverage probability and its 95%
 280 confidence interval for propensity score specification strategies M1 to M6 for different cluster structure and cluster level
 281 confounder odd ratio on treatment outcome. Structure = (number of clusters, individuals per cluster), surgeon OR = cluster
 282 level confounder odd ratio on treatment outcome. Propensity score(PS) strategies: M1 = logistic regression PS excluding
 283 cluster-level confounders; M2 = logistic regression PS including cluster-level confounders, M3 = logistic regression PS with
 284 cluster level confounders and cross level interaction term, M4 = random effects PS excluding cluster-level confounders, M5 =
 285 random effects PS including cluster-level confounders, M6 = random effects PS with cluster level confounders and cross level
 286 interaction term . The black vertical dotted line indicates 95%.



287

288


289

290

291

292 Real world case study

293 *Figure 5: Treatment effects estimates in relative risk and its 95% confidence interval using data from the UTMOST study and*
294 *the six proposed propensity score strategies M1 To M6 and also the TOPKAT surgical trial estimates. TOPKAT = surgical trial*
295 *estimates. Propensity score(PS) strategies: M1 = logistic regression PS excluding cluster-level confounders; M2 = logistic*
296 *regression PS including cluster-level confounders, M3 = logistic regression PS with cluster level confounders and cross level*
297 *interaction term, M4 = random effects PS excluding cluster-level confounders, M5 = random effects PS including cluster-*
298 *level confounders, M6 = random effects PS with cluster level confounders and cross level interaction term*



299

300 Figure 5 gives the treatment effect estimates using the six propensity score strategies (M1 to M6)
301 proposed for the case study (UTMOST) and the TOPKAT surgical trial estimates. We found that
302 under all model strategies, UKR had a higher risk for 5-year revision than TKR. In contrast, TOPKAT
303 found no statistically significant difference in the revision risk between UKR and TKR. Models that
304 incorporated multilevel data or not or/and included the cluster-level confounders in the propensity
305 score model had an overlapping confidence interval of outcome estimates. This meant all six
306 proposed propensity score strategies (M1 to M6) gave similar treatment estimates and were not
307 statistically significantly different. In addition, propensity score models with and without cross level

308 interaction term had similar estimates (M2 vs M3, M5 vs M6), suggesting that adding the cross level

309 interaction term in the propensity score models did not impact the estimate.

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327 CONCLUSION AND DISCUSSION

328 Discussion

329 This study aimed to find the best way to account for cluster level confounding in propensity score
330 model for propensity score weighting analysis when random effects model was used to estimate the
331 treatment outcome. In our simulation study, we found accounting for the cluster level confounders
332 in the propensity score model when random effects model was used as the outcome model does not
333 always give the smallest bias. For cluster structures with small cluster number and large cluster size
334 ($m = 10, n = 1000$) and ($m = 50, n = 200$), strategy that ignored the cluster level confounders (M1)
335 performed the best. Including the cluster level confounders in the propensity score model by using
336 random effects model and as covariates in the model only offered improvement in bias for small
337 cluster size scenarios ($m = 500, n = 20$). This is consistent with previous studies on propensity score
338 for clustered data(7, 8, 12), which shows random effects model might give more accurate estimation
339 in propensity score compared to logistics regression but not necessary improvement in accuracy for
340 treatment estimation. However in our simulation study we also showed the optimal propensity
341 score model strategy were dependent on clustered structure and cluster level confounder effect on
342 outcome. Whereas previous simulations study(8, 12) on this topic were more focus on the
343 performance of different weighting approaches. We also found that adding the cross-level
344 interaction term made little impact to the treatment effect in the simulation study.

345 Applying the proposed propensity score strategies to real-world clinical study corroborated with
346 some but not all our simulation results. Including a cross-level interaction term in either the logistic
347 regression or random effects model did not substantially change the estimated treatment effect,
348 same as the simulation study result. However, the treatment effect estimates in the real-world
349 clinical study all had overlapping confidence intervals, meaning all six propensity score strategies
350 (M1 to M6) gave similar results, different from our simulation results. There were few differences
351 between the cluster structure, which could contribute to these differences in the result. First, the

352 cluster size was fixed in the simulation study, but the cluster size was varied for the real-world
353 clinical study. Second, we found that many surgeons only carried out one type of treatment in the
354 real-world clinical study. However, in our simulation study, the treatment is allocated individually,
355 meaning both treatments can appear in all clusters. This discrepancy of results between our real-
356 world clinical study and simulation also highlighted that the cluster structure of the data affects the
357 accuracy and precision of results for propensity score weighting analysis. More research is needed
358 on how different cluster structures affect propensity score weighting analysis.

359 **Strengths and Limitation of the study**

360 This study's main strength is its use of both simulations and real-world data. Using simulated data,
361 where the true average treatment effect was known, allowed us to compare the accuracy of the six
362 proposed PS estimation strategies. Using clinical data allowed us to test whether the trends from the
363 simulation study were held with real-world data.

364 This study has several limitations. In the simulation study, we investigated only fixed cluster number
365 and size scenarios in the scenarios. Our real-world case study found the simulation findings may not
366 be able to generalise to the scenario when cluster number and size was not fixed. In addition, we
367 only tested the propensity score strategies on binary outcomes. Therefore, our results cannot
368 generalise to other types of outcomes. We also assumed that the treatment assignment was only
369 influenced by a small set of covariates in the simulation study. It could be argued that in real world
370 settings, the data would usually contain more covariates. However, the focus of this study was not
371 on covariates number. Finally, the TOPKAT trial treatment estimate was underpowered in the real-
372 world case study. As a result, the 95% confidence interval for the trial treatment estimate was large,
373 making it difficult to compare the accuracy of the treatment effects from the UTMOST data.

374

375

376 **Conclusion**

377 In summary, careful consideration of the cluster structure is necessary to decide on whether to use a
378 random effects model on propensity score estimation. We should only consider using random
379 effects model for propensity score model when the dataset contains large numbers of small clusters.
380 Also, we should consider including cluster level confounders as covariates in the propensity score
381 model when the cluster level confounders are thought to strongly affect the treatment outcome, as
382 this can reduce bias.

383

384

385

386

387

388

389

390

391

392

393

394

395

396 **REFERENCES**

- 397 1. Bernard A, Vaneau M, Fournel I, Galmiche H, Nony P, Dubernard JM. Methodological choices
398 for the clinical development of medical devices. *Med Devices (Auckl)*. 2014;7:325-34.
- 399 2. ROSENBAUM PR, RUBIN DB. The central role of the propensity score in observational studies
400 for causal effects. *Biometrika*. 1983;70(1):41-55.
- 401 3. Rosenbaum PR, Rubin DB. Reducing Bias in Observational Studies Using Subclassification on
402 the Propensity Score. *Journal of the American Statistical Association*. 1984;79(387):516-24.
- 403 4. Papachristofi O, Klein AA, Mackay J, Nashef S, Fletcher N, Sharples LD, et al. Effect of
404 individual patient risk, centre, surgeon and anaesthetist on length of stay in hospital after cardiac
405 surgery: Association of Cardiothoracic Anaesthesia and Critical Care (ACTACC) consecutive cases
406 series study of 10 UK specialist centres. *BMJ Open [Internet]*. 2017 2017/09//; 7(9):[e016947 p.].
407 Available from: <http://europepmc.org/abstract/MED/28893748>
- 408 <https://doi.org/10.1136/bmjopen-2017-016947>
- 409 <https://europepmc.org/articles/PMC5595188>
- 410 <https://europepmc.org/articles/PMC5595188?pdf=render>.
- 411 5. Montgomery K, Schneller ES. Hospitals' strategies for orchestrating selection of physician
412 preference items. *Milbank Q*. 2007;85(2):307-35.
- 413 6. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an
414 update. *Contemporary clinical trials*. 2007;28(2):105-14.
- 415 7. Arpino B, Mealli F. The specification of the propensity score in multilevel observational
416 studies. *Comput Stat Data Anal*. 2011;55(4):1770-80.
- 417 8. Li F, Zaslavsky AM, Landrum MB. Propensity score weighting with multilevel data. *Statistics*
418 *in Medicine*. 2013;32(19):3373-87.
- 419 9. Schuler MS, Chu WH, Coffman D. Propensity score weighting for a continuous exposure with
420 multilevel data. *Health Services and Outcomes Research Methodology*. 2016;16(4):271-92.
- 421 10. Yang S. Propensity Score Weighting for Causal Inference with Clustered Data. *J Causal*
422 *Inference*. 2018;6(2):19.
- 423 11. Cafri G, Austin PC. Propensity score methods for time-dependent cluster confounding. *Biom*
424 *J*. 2020;62(6):1443-62.
- 425 12. Fuentes A, Lüdtke O, Robitzsch A. Causal Inference with Multilevel Data: A Comparison of
426 Different Propensity Score Weighting Approaches. *Multivariate Behavioral Research*. 2021:1-24.
- 427 13. Raychaudhuri S, editor Introduction to Monte Carlo simulation. 2008 Winter Simulation
428 Conference; 2008 7-10 Dec. 2008.
- 429 14. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse
430 propensity scores as weights to directly estimate relative risk and its confidence intervals. *Value*
431 *Health*. 2010;13(2):273-7.
- 432 15. Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods.
433 *Statistics in Medicine*. 2019;38(11):2074-102.
- 434 16. Prats-Urbe A, Kolovos S, Berencsi K, Carr A, Judge A, Silman A, et al. Unicompartmental
435 compared with total knee replacement for patients with multimorbidities: a cohort study using
436 propensity score stratification and inverse probability weighting. *Health Technol Assess*.
437 2021;25(66):1-126.
- 438 17. Beard DJ, Davies LJ, Cook JA, MacLennan G, Price A, Kent S, et al. The clinical and cost-
439 effectiveness of total versus partial knee replacement in patients with medial compartment
440 osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. *The Lancet*.
441 2019;394(10200):746-56.
- 442 18. Wilson HA, Middleton R, Abram SGF, Smith S, Alvand A, Jackson WF, et al. Patient relevant
443 outcomes of unicompartmental versus total knee replacement: systematic review and meta-
444 analysis. *BMJ*. 2019;364:l352.

445

446 **Abbreviations:** PS, propensity score; OR, odd ratio; REM, random effects model; MSE, mean square
447 error; UKR, unicompartmental knee replacement; TKR, total knee replacement; NJR, UK National
448 Joint Registry

449